Audio

Community Oncology Podcast - HER2-positive metastatic breast cancer


 

Axitinib in renal cell carcinoma, pertuzumab plus trastuzumab and docetaxel in HER2-positive metastatic breast cancer, and models for including psychosocial services into community oncology practices are featured in the February podcast of Community Oncology, hosted by Editor-in-Chief Dr. David Henry.

Recommended Reading

Trastuzumab Bests Lapatinib for HER2 Breast Cancer
MDedge Hematology and Oncology
Bevacizumab Boosts Treatment Responses in Early Breast Cancer
MDedge Hematology and Oncology
Re-Excision Rates After Breast-Conserving Surgery Vary Greatly
MDedge Hematology and Oncology
Breast Cancer Drug Exemestane Linked to BMD Loss
MDedge Hematology and Oncology
Breast Cancer Mortality Rises with Age in Older Women
MDedge Hematology and Oncology
Lynch Syndrome Linked to Breast, Pancreatic Cancers
MDedge Hematology and Oncology
NICE Nixes Lapatinib, Trastuzumab With Aromatase Inhibitors for Some Breast Cancer
MDedge Hematology and Oncology
ACOG Releases Guideline for Breast Cancer Management
MDedge Hematology and Oncology
VEGF-Targeting Cancer Drugs Raise Risk of Fatal Side Effects
MDedge Hematology and Oncology
Pertuzumab plus trastuzumab and docetaxel in HER2-positive metastatic breast cancer
MDedge Hematology and Oncology